Skip to main content

Table 7 Characteristics and outcome of canine patients treated with chemotherapy alone for refractory cancers

From: Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

PATIENT AGE TUMOR PREV.
TREATMENT
THERAPY OUTCOME
(MONTHS)
MIXED 11 LSA MADISON +
MOPP
MADISON PD 1
SETTER 6 ALL MADISON +
MOPP
MADISON PD 1
BOXER 9 SKIN
CARCINOMA
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PR 2
WHWT 8 LSA MADISON +
MOPP
MADISON PR 1
ROTTW 7 LSA MADISON +
MOPP
MADISON PR 3
GERMAN 9 LSA MADISON +
MOPP
MADISON PD 1
SHEPHERD    MOPP   
LABRADOR 9 LSA MADISON +
MOPP
MOPP PD 2
MIXED 10 MAMMARY
CARCINOMA
DOXORUBICIN
CARBOPLATIN
DOXORUBICIN PR 1
DOGO 10 LIPOSARCOMA DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PD 1
MIXED 10 MAMMARY
CARCINOMA
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PR 2
  1. Abbreviations: ALL: acute lymphocytic leukemia; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; WHWT: west highland white terrier.
  2. Drugs schedule: doxorubicin 30 mg/m2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m2 every 21 days, mitoxantrone 6 mg/m2 every 21 days. For Madison and MOPP protocols see table 4 and 5.